Articles
-
Feb 11, 2025 |
aws.amazon.com | Ian McRae |Balaji Raman |Tim Nguyen
If your institution controls sensitive data, you know that trust is your most important asset. At Amazon Web Services (AWS), we have seen requests for collaboration using sensitive datasets grow in number and complexity as more value is unlocked through novel research techniques and cutting-edge research topics. Enabling this collaboration while making sure requests for data transfer are appropriately reviewed helps you maintain trust with your data owners and meet compliance obligations.
-
Aug 16, 2024 |
australiannationalreview.com | Tim Nguyen
Danish drugmaker Bavarian Nordic is poised to begin large-scale production of its monkeypox vaccine. The company’s rapid response comes in the wake of the World Health Organization’s (WHO) recent declaration of a global health emergency concerning the monkeypox outbreak. The WHO’s emergency committee convened amid alarming reports of a more virulent strain of monkeypox spreading across four additional regions in Africa.
-
Dec 15, 2023 |
cancernetwork.com | Suneel Kamath |Joanna Roopkumar |Ying Ni |Minqian Shen |Pablo G. Bejarano |Daniela Allende | +9 more
December 15, 2023OncologyONCOLOGY Vol 37, Issue 12Pages: 488-495Suneel K. Kamath, MD, et al investigated exceptional responders and the correlation of nonsynonymous mutations for patients with advanced pancreatic cancer. ABSTRACTIntroduction: Exceptional response to therapy is rare in patients with advanced pancreatic cancer. This study explored potential genomic differences between typical and exceptional responses that could confer more favorable biology.
-
Dec 15, 2023 |
December 15, 2023OncologyONCOLOGY Vol 37, Issue 12Pages: 488-495Suneel K. Kamath, MD, et al investigated exceptional responders and the correlation of nonsynonymous mutations for patients with advanced pancreatic cancer. ABSTRACTIntroduction: Exceptional response to therapy is rare in patients with advanced pancreatic cancer. This study explored potential genomic differences between typical and exceptional responses that could confer more favorable biology.
-
Dec 15, 2023 |
December 15, 2023OncologyONCOLOGY Vol 37, Issue 12Pages: 488-495Suneel K. Kamath, MD, et al investigated exceptional responders and the correlation of nonsynonymous mutations for patients with advanced pancreatic cancer. ABSTRACTIntroduction: Exceptional response to therapy is rare in patients with advanced pancreatic cancer. This study explored potential genomic differences between typical and exceptional responses that could confer more favorable biology.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →